Ketazocine

Ketazocine
Clinical data
Routes of; administration	Oral
ATC code	none;
Identifiers
	IUPAC name (2S,6R,11R)-3-(cyclopropylmethyl)-8-hydroxy-6,11-dimethyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2H)-one;
CAS Number	36292-69-0 ;
PubChem CID	3054741;
ChemSpider	2316328 ;
UNII	6IO4IG518S;
KEGG	D04649 ;
CompTox Dashboard (EPA)	DTXSID10897529 ;
Chemical and physical data
Formula	C18H23NO2
Molar mass	285.387 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2c1c(cc(O)cc1)[C@]3([C@H]([C@@H]2N(CC3)CC4CC4)C)C;
	InChI InChI=1S/C18H23NO2/c1-11-16-17(21)14-6-5-13(20)9-15(14)18(11,2)7-8-19(16)10-12-3-4-12/h5-6,9,11-12,16,20H,3-4,7-8,10H2,1-2H3/t11-,16-,18+/m0/s1 ; Key:HQBZLVPZOGIAIQ-SDDDUWNISA-N ;
	(verify)

Ketazocine (INN), also known as ketocyclazocine, is a benzomorphan derivative used in opioid receptor research. Ketocyclazocine is an exogenous opioid that binds to the κ opioid receptor.^[1]

Activation of this receptor is known to cause sleepiness, a decrease in pain sensation and (potentially) dysphoria, paranoia, and hallucinations. It also causes an increase in urine production because it inhibits the release of vasopressin. (Vasopressin is an endogenous substance that assists in regulating fluid and electrolyte balance in the body and decreases the amount of water released into the urine.)

Unlike other opioids, substances that only bind to the κ receptor theoretically do not depress the respiratory system.

References

^ Leander JD (September 1982). "Effects of ketazocine, ethylketazocine and phenazocine on schedule-controlled behavior: antagonism by naloxone". Neuropharmacology. 21 (9): 923–8. doi:10.1016/0028-3908(82)90085-5. PMID 6128693.

[1] Leander JD (September 1982). "Effects of ketazocine, ethylketazocine and phenazocine on schedule-controlled behavior: antagonism by naloxone". Neuropharmacology. 21 (9): 923–8. doi:10.1016/0028-3908(82)90085-5. PMID 6128693.

[1]

See also

References